Comparison Analysis of Adverse Drug Reactions of Rivaroxaban and Apixaban Based on OpenFDA

doi:10.19803/j.1672-8629.2021.08.18

Abstract

Abstract: Objective To search for reports of adverse reactions caused by oral anticoagulant drugs-rivaroxaban and apixaban by using openFDA, and compare the adverse reactions of the two drugs in order to provide reference for clinical rational drug use. Methods Reports of adverse reactions caused by rivaroxaban and apixaban that were submitted between January 1, 2004 and August 12, 2019 to the openFDA database were searched for using the interactive chart section access API for Adverse Drug Reaction Endpoints. Relevant data and charts were retrieved and analyzed. Results There were 6 676 and 10 513 ADR reports of rivaroxaban and apixaban respectively, which were mostly reported by doctors. The adverse reactions occurred in the United States, and the affected population ranged from 65 to 82 years old. Rivaroxaban and apixaban could be used for the prevention and treatment of deep vein thrombosis and pulmonary embolism, but the main adverse reaction was bleeding. Conclusion Based on the openFDA large databases, the ADR related information of the two drugs can be analyzed, which provides data for effective drug monitoring and immediate treatment of adverse reactions, but the data has some flaws and needs to be improved.

Key words: rivaroxaban, apixaban, openFDA, adverse drug reactions

CLC Number:

R994.1

LING Tao, XU Ruijuan, GE Weihong. Comparison Analysis of Adverse Drug Reactions of Rivaroxaban and Apixaban Based on OpenFDA[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 780-783.

References

[1] Panahi Y, Rahimnia AR, Sharafi M,et al.Curcuminoid treatment for knee osteoarthritis: a randomized double-blind, placebo-controlled trial[J]. Phytother Res, 2015, 28(11): 1625-1631.
[2] Liang P, Li SL.Advances in the clinical treatment of knee osteoarthritis[J]. Chinese Journal of Traditional Medical Traumat-ology & Orthopedics(中医骨伤科杂志), 2006, 14(3): 65-67.
[3] Chinese Orthopaedic Association.Chinese guidelines for the prevention of venous thromboembolism during major orthopedic operations[J]. Chinese Journal of Joint Surgery(中华关节外科杂志),2009, 36(3): 65-71.
[4] Lassen MR, Davidson BL, Gallus A, et al.The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement[J]. Journal of Thrombosis and Haemostasis, 2007, 5(12): 2368-2375.
[5] Li XQ, Zhang FX, Wang SM.Guidelines for the diagnosis and treatment of deep vein thrombosis (3rd Edition)[J]. Chinese Journal of Vascular Surgery(中国血管外科杂志), 2017, 32(9): 807-812.
[6] Li SQ.Antithrombotic therapy for venous thromboembolism-interpretation of the american college of chest physicians' clinical practice guidelines for evidence-based medicine (9th edition)[J]. Journal of Clinical Military Medicine(临床军医杂志), 2013, 41(6): 647-650.
[7] Kubitza D, Becka M, Voith B, et al.Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor[J]. Clinical Pharmacology & Therapeutics, 2005, 78(4): 412-421.
[8] Weisz C, Buetehorn U, Daehler HP, et al.Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs[J]. Xenobiotica, 2005, 35(9): 891-910.
[9] Gradman AH, Wilson JT.Hypertension and diastolic heart failure[J]. Current Cardiology Reports, 2009, 11(6): 422-429.
[10] Yang X, Dong SJ, Zhai SD.Meta-analysis on the efficacy and safety of rivaroxaban in the prevention of venous thromboembolism in patients after orthopaedic surgery[J]. Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2017, 33(14): 1366-1370.
[11] Wen L, Han X, Zhou H.Response to novel oral anticoagulants dabigatun and rivaroxaban associated bleeding[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(1): 15-18.
[12] Bao X.Introduction to the openFDA public health program[J]. China Licensed Pharmacist(中国执业药师), 2015, 12(10): 18-22.
[13] DXY. FDA launches openFDA program to open health database to the public[EB/OL]. (2016-10-07) [2019-12-01]. http://yao.dxy.cn/article/77205.
[14] FDA. OpenFDA/download[EB/OL].(2016-10-07) [2019-12-01]. https://open.fda.gov/downloads/. 2016.
[15] Zong X, Wang YL.The enlightenment of openFDA data disclosure to China’s food and Drug regulatory data management[J]. Chinese Pharmacy(中国药房), 2017, 31(9): 976-979.
[16] Duan R, Li ZX.Based on openFDA's analysis and research on the adverse reactions after the net marketing of Daggeret[J]. Chinese Journal of Hospital pharmacy(中国医院药学杂志), 2018, 38(22): 2360-2362.
[17] Meng L, Tang XW, Ji HH, et al.The signal mining and evaluation of statin-related adverse reactions is based on the data mining research of the openFDA Public Data Open Project in the United States[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(2): 244-248.
[18] Shi HW, Chen Y, Yao J, et al.Analysis of pirospirone ethinyle-stradiol tablets in Open FDA Public Data Program[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(9): 552-555.